Redbiotec AG produces multi-component virus-like particles (reVLPs®) and other protein complexes for the use as novel vaccines and biologics. These protein assemblies are produced using Redbiotec’s proprietary protein co-expression platform (rePAX® technology). The main focus of the company is the generation of vaccine products to prevent Herpesvirus infections. Redbiotec also has programs against other viral diseases such as influenza. Redbiotec AG was founded in 2006 as spin-off from the ETH Zürich and is located in the Bio-Technopark Schlieren-Zürich in Switzerland. For more information please visit www.redbiotec.ch.